Literature DB >> 2646359

The "natural history" of ulcerative colitis: an analysis of the placebo response.

S Meyers1, H D Janowitz.   

Abstract

We have attempted to elucidate the "natural history" of ulcerative colitis by studying the placebo groups of 11 controlled trials of 185 patients with active disease. Most (182) of the patients were mild to moderately ill, but 3 had severe colitis. They were studied by endoscopic, pathologic, and/or clinical criteria and followed for 15-42 days. Up to 52% improved clinically and 59% sigmoidoscopically. Relapses commonly occurred within 2 months of these "spontaneous" improvements. In another six trials of 174 patients in remission receiving only placebo therapy (134 followed for 6 months and 40 for 12 months), up to 51% remained in remission. Favorable predictive factors for continued remission included a normal rectal mucosa on sigmoidoscopy, limited extent of colitis, and remission recently achieved by active therapy or maintained by therapy for at least 1 year before study entry. Thus, patients can get and stay better with no "specific" therapy. We have clarified advantageous predictive factors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2646359     DOI: 10.1097/00004836-198902000-00008

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  11 in total

Review 1.  Radical induction theory of ulcerative colitis.

Authors:  Jay Pravda
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

2.  Meta-analysis of the placebo response in ulcerative colitis.

Authors:  Sagar Garud; Alphonso Brown; Adam Cheifetz; Emily B Levitan; Ciaran P Kelly
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

Review 3.  Positioning Therapy for Ulcerative Colitis.

Authors:  Ari Grinspan; Asher Kornbluth
Journal:  Curr Gastroenterol Rep       Date:  2015-08

Review 4.  Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

Authors:  S B Hanauer; G Stathopoulos
Journal:  Drug Saf       Date:  1991 May-Jun       Impact factor: 5.606

5.  Low-dose oral methotrexate in refractory inflammatory bowel disease.

Authors:  T H Baron; C D Truss; C O Elson
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

6.  Pros and cons of medical management of ulcerative colitis.

Authors:  Udayakumar Navaneethan; Bo Shen
Journal:  Clin Colon Rectal Surg       Date:  2010-12

7.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.

Authors:  J K Marshall; E J Irvine
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

Review 8.  The placebo effect: illness and interpersonal healing.

Authors:  Franklin G Miller; Luana Colloca; Ted J Kaptchuk
Journal:  Perspect Biol Med       Date:  2009       Impact factor: 1.416

9.  Rectal administration of d-alpha tocopherol for active ulcerative colitis: a preliminary report.

Authors:  Seyed-Amir Mirbagheri; Behtash-Ghazi Nezami; Solmaz Assa; Mannan Hajimahmoodi
Journal:  World J Gastroenterol       Date:  2008-10-21       Impact factor: 5.742

Review 10.  New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance.

Authors:  Kartikeya Tripathi; Joseph D Feuerstein
Journal:  Drugs Context       Date:  2019-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.